Literature DB >> 9498456

Granulocytic ehrlichiosis in the laboratory mouse.

E Hodzic1, J W Ijdo, S Feng, P Katavolos, W Sun, C H Maretzki, D Fish, E Fikrig, S R Telford, S W Barthold.   

Abstract

C3H mice that were inoculated with ehrlichiae isolated from a patient with human granulocytic ehrlichiosis (HGE) developed anemia and leukopenia, but by day 24, they returned to normal values. Granulocytic morulae were present in peripheral blood and spleen smears on days 5 and 10, and there was a reduction in morulae on day 17. Ehrlichiae were present in HL-60 cell cultures of blood and spleen from all mice at all intervals. Pathogenicity, but not infectivity, waned with mouse passage but could be resurrected by SCID mouse passage. Various methods were tested for their relative sensitivity in detecting infection: blood smears, HL-60 cell cultures, polymerase chain reaction (PCR) amplification of a 16S recombinant DNA target, and a mouse infectivity assay. All assays detected the HGE agent in blood during early infection, but PCR and the mouse infectivity assay were most sensitive during late infection. Xenodiagnosis demonstrated that mice remain persistently infected through 55 days.

Entities:  

Mesh:

Year:  1998        PMID: 9498456     DOI: 10.1086/514236

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  30 in total

1.  Infection with Anaplasma phagocytophilum induces multilineage alterations in hematopoietic progenitor cells and peripheral blood cells.

Authors:  J L Johns; K C Macnamara; N J Walker; G M Winslow; D L Borjesson
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

Review 2.  Mechanisms of obligatory intracellular infection with Anaplasma phagocytophilum.

Authors:  Yasuko Rikihisa
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

3.  Experimental infection of white-tailed deer with Anaplasma phagocytophilum, etiologic agent of human granulocytic anaplasmosis.

Authors:  Cynthia M Tate; Daniel G Mead; M Page Luttrell; Elizabeth W Howerth; Vivien G Dugan; Ulrike G Munderloh; William R Davidson
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

4.  Receptor interacting protein-2 contributes to host defense against Anaplasma phagocytophilum infection.

Authors:  Bindu Sukumaran; Yasunori Ogura; Joao H F Pedra; Koichi S Kobayashi; Richard A Flavell; Erol Fikrig
Journal:  FEMS Immunol Med Microbiol       Date:  2012-07-23

5.  Granulocytic ehrlichiosis in mice deficient in phagocyte oxidase or inducible nitric oxide synthase.

Authors:  R Banerjee; J Anguita; E Fikrig
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

6.  Pathogen-mediated manipulation of arthropod microbiota to promote infection.

Authors:  Nabil M Abraham; Lei Liu; Brandon Lyon Jutras; Akhilesh K Yadav; Sukanya Narasimhan; Vissagan Gopalakrishnan; Juliana M Ansari; Kimberly K Jefferson; Felipe Cava; Christine Jacobs-Wagner; Erol Fikrig
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

7.  Coinfection with Borrelia burgdorferi and the agent of human granulocytic ehrlichiosis alters murine immune responses, pathogen burden, and severity of Lyme arthritis.

Authors:  V Thomas; J Anguita; S W Barthold; E Fikrig
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

8.  Persistence of Anaplasma ovis infection and conservation of the msp-2 and msp-3 multigene families within the genus Anaplasma.

Authors:  G H Palmer; J R Abbott; D M French; T F McElwain
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

9.  Outcomes of treated human granulocytic ehrlichiosis cases.

Authors:  Alan H Ramsey; Edward A Belongia; Craig M Gale; Jeffrey P Davis
Journal:  Emerg Infect Dis       Date:  2002-04       Impact factor: 6.883

10.  Seasonal dynamics of Anaplasma phagocytophila in a rodent-tick (Ixodes trianguliceps) system, United Kingdom.

Authors:  Kevin J Bown; Michael Begon; Malcolm Bennett; Zerai Woldehiwet; Nicholas H Ogden
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.